Research Article

Zhisong Yang#, Li Zhou#, Haiyan Ge, Weimin Shen, Lin Shan*

Identification of autophagy-related biomarkers in patients with pulmonary arterial hypertension based on bioinformatics analysis

https://doi.org/10.1515/med-2022-0497
received January 20, 2022; accepted May 9, 2022

Abstract: Autophagy participates in the regulation of pulmonary arterial hypertension (PAH). However, the role of autophagy-related genes (ARGs) in the pathogenesis of the PAH is still unclear. This study aimed to identify the ARGs in PAH via bioinformatics analysis. A microarray dataset (GSE113439) was downloaded from the Gene Expression Omnibus database to identify differentially expressed ARGs (DEARGs). Protein–protein interactions network, gene ontology, and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed to screen hub genes and the underlying molecular mechanisms of PAH. Finally, the mRNA expression of the hub genes was validated using the GSE53408 dataset. Twenty-six DEARGs were identified, all of which were upregulated. Enrichment analyses revealed that these DEARGs were mainly enriched in the nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway, PI3K-Akt signaling pathway, response to hypoxia, response to nutrient levels, and autophagy. Among these hub genes, the mRNA expression levels of HSP90AA1, HIF1A, MET, IGF1, LRRK2, CLTC, DNM1L, MDM2, RICTOR, and ROCK2 were significantly upregulated in PAH patients than in healthy individuals. Ten hub DEARGs were identified and may participate in the pathogenesis of the PAH via the regulation of autophagy. The present study may provide novel therapeutic targets for PAH prevention and treatment and expand our understanding of PAH.

Keywords: cardiopulmonary disease, congenital heart disease, hub genes, bioinformatics analyses, autophagy

1 Introduction

Pulmonary arterial hypertension (PAH) is a multifactorial cardiopulmonary disease, in which vascular thickening is one of the main factors that cause right ventricle failure and cardiac dysfunctions [1]. The annual prevalence of PAH is 15–50 cases per million people, and its incidence is 5–10 cases per million people [2]. Based on clinical classification criteria, PAH can be divided into toxin- and drug-evoked PAH, heritable PAH, idiopathic PAH, PAH with congenital heart disease (CHD), PAH with portal hypertension, PAH with the connective disease, and so on [3]. Patients with PAH and cardiomyopathy usually have a poor prognosis, compared to patients with simple cardiomyopathy, the incidence of atrial fibrillation was higher [4,5]. The pathogenesis of PAH is complex and there is no curative treatment therapy at present. In recent years, advances in effective drug therapy and the use of combination therapy have significantly improved the prognosis of patients with PAH [6,7]. Although previous reports have demonstrated that many biomarkers and related pathways were implicated in the pathological process of PAH, the precise molecular mechanism is still not fully understood [8,9]. Therefore, the investigation of novel biomarkers for PAH is not only important to better understand the pathobiology of PAH, but is also an important way to establish promising new treatment strategies [10].

Autophagy is an important and complex homeostasis process implicated in survival mechanisms and cellular homeostasis in eukaryotes [11]. The impaired level of autophagy participates in the regulation of various diseases, including neurodegenerative diseases, cancer, metabolic diseases, and chronic respiratory disease [12]. Previous reports have demonstrated that lung cancer, lung injury,
PAH, idiopathic pulmonary diseases, and other pulmonary diseases are associated with abnormal autophagy [13]. For example, PDIA6 was reported to modulate cisplatin-induced autophagy and apoptosis in non-small cell lung cancer by inhibiting the JNK/c-Jun signaling pathway [14]. Ghrelin was revealed to restrain chronic obstructive pulmonary disease-associated autophagy and inflammation [15]. Moreover, it has been demonstrated that nuclear receptor binding SET domain 2 (NSD2) participates in the progression of monocrotaline-evoked PAH via the regulation of autophagy and trehalose metabolism [16]. Adenosine monophosphate-activated protein kinase (AMPK) activation suppresses the development of PAH via inhibiting vascular remodeling and autophagy [17]. Therefore, identifying the autophagy-related genes may provide us with potential therapeutic targets for PAH. To date, there are still few reports about PAH and autophagy, as most of them only focused on autophagy-related targets in vivo or in vitro.

The present study aimed to investigate the differentially expressed autophagy-related genes (DEARGs) of PAH from the GSE113439 dataset. Protein–protein interaction (PPI) network was constructed by using Cytoscape software to identify hub genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were carried out to investigate the molecular mechanisms of PAH.

2 Materials and methods

2.1 Data resources

The GSE113439 and GSE53408 datasets were downloaded from the Gene Expression Omnibus database. GSE113439 contained 11 normal controls and four patients with PAH and CHD. GSE53408 contained 11 healthy individuals and 12 severe pulmonary arterial hypertension patients.

2.2 Identification of DEARGs

The limma package in R software was used to screen the DEGs between normal samples and PAH samples. |log2FC| ≥1 and P-value <0.05 was defined as criteria for DEGs identification [18]. The autophagy-related genes (ARGs) were collected from the Human Autophagy-dedicated Database (http://hamdb.scbdd.com/). Then, we used a Venn diagram package to identify DEARGs. The “ggplot2” and “heatmap” packages of R software were used to draw the volcano plot and heatmap.

2.3 KEGG and gene ontology (GO)-biological process (BP) enrichment analyses

KEGG pathway and GO-BP enrichment analyses were carried out using Metascape (http://metascape.org/). The result with P < 0.05 was considered statistically significant. The visualization of the enriched pathways was carried out using the clusterProfiler (4.2.1) package in R software.

2.4 PPI network construction and hub genes identification

STRING database and Cytoscape software were used to construct and visualize the PPI network of DEARGs. Cytohubba plugin in the Cytoscape was used to identify the hub genes based on the degree algorithm [19].

2.5 Statistical analysis

Gene expression values between control and PAH samples were compared using Student’s t-tests. P < 0.05 was
considered statistically significant. The receiver operating characteristic (ROC) was carried out to access the diagnostic value of potential targets, with the area under the curve (AUC) indicating specificity and sensitivity.

**Ethics approval and informed consent:** The present study was carried out based on public databases, so approval was not required for this study by the ethics committee and there are no ethical issues or other conflicts of interest.

### 3 Results

#### 3.1 Identification of DEGs and DEARGs

We identified 627 DEGs between control samples and PAH samples in the GSE113439 dataset, including 530 upregulated genes and 97 downregulated genes. The heatmap of 627 DEGs are presented in Figure 1. Next, we collected 796 ARGs from the Human Autophagy-dedicated Database. A

![Figure 2](image-url)

**Figure 2:** Identification of autophagy-related genes in patients with PAH and CHD: (a) Venn map indicating the intersection genes of ARGs and DEGs in GSE113439, (b) clustered heatmap of DEARGs in GSE113439, and (c) volcano plot of all genes in GSE113439, DEARGs marked in the diagram.
total of 26 DEARGs were obtained by combining the results of 627 DEGs and 796 ARGs (Figure 2a). The heatmap and volcano plot of 26 DEARGs are presented in Figure 2b and c. Interestingly, all the DEARGs were upregulated.

3.2 Enrichment analysis of DEARGs

We performed functional enrichment analyses, including KEGG and GO-BP enrichment analyses to further investigate the biological function of DEARGs in PAH. Our results revealed that DEARGs were significantly enriched in proteoglycans in cancer, oxytocin signaling pathway, nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway, pathways in cancer, focal adhesion, vascular smooth muscle contraction, platelet activation, and PI3K-Akt signaling pathway. As presented in Figure 3 and Table 1, DEARGs such as IGF1, ITPR2, PLA2G4A, HIF1A, MET, OPA1, ERBIN, CD38, and LRRK2 were the ones involved in long-term depression. DEARGs such as

![Figure 3: Sankey plot of KEGG enrichment analysis of DEARGs.](image)

**Table 1: KEGG analysis of DEARGs in PAH (top ten listed)**

| Description                                | Gene ratio | P value          | Symbols                                                                 | Count |
|--------------------------------------------|------------|-----------------|-------------------------------------------------------------------------|-------|
| Proteoglycans in cancer                    | 0.0689655  | 3.26789 x 10^{-10} | HIF1A/IGF1/ITPR2/MDM2/MET/ROCK1/ROCK2/OPA1/DNM1L/RICTOR/HSP90AA1/SPPI/CFLAR/CLTC | 14    |
| Oxytocin signaling pathway                 | 0.0328947  | 1.81365 x 10^{-7} | CD38/ITPR2/PLA2G4A/ROCK1/ROCK2                                         | 5     |
| NOD-like receptor signaling pathway        | 0.0588235  | 3.16322 x 10^{-7} | CYBB/HSP90AA1/ITPR2/DNM1L/ERBIN/MDM2/EIF2S1/EIF2AK2/CLTC/RICTOR         | 10    |
| Pathways in cancer                         | 0.0121528  | 4.21189 x 10^{-7} | HIF1A/HSP90AA1/IGF1/MDM2/MET/ROCK1/ROCK2                                | 7     |
| Focal adhesion                             | 0.0251256  | 6.8965 x 10^{-7}  | IGF1/MET/ROCK1/SPPI/ROCK2                                               | 5     |
| Vascular smooth muscle contraction         | 0.0330579  | 3.4048 x 10^{-6}  | ITPR2/PLA2G4A/ROCK1/ROCK2                                              | 4     |
| Platelet activation                        | 0.0307692  | 4.52862 x 10^{-6} | ITPR2/PLA2G4A/ROCK1/ROCK2                                              | 4     |
| PI3K-Akt signaling pathway                 | 0.0146199  | 9.72001 x 10^{-6} | HSP90AA1/IGF1/MDM2/MET/SPPI                                            | 5     |
| Long-term depression                       | 0.15       | 1.86851 x 10^{-5} | IGF1/ITPR2/PLA2G4A/HIF1A/OPA1/ERBIN/CD38/LLRK2                         | 9     |
| Melanoma                                   | 0.0434783  | 2.84622 x 10^{-5} | IGF1/MDM2/ERBIN                                                         | 3     |
CYBB, HSP90AA1, ITPR2, DNMI1, ERBIN, MDM2, EIF2S1, EIF2AK2, CLTC, and RICTOR were the ones associated with the NOD-like receptor signaling pathway. DEARGs such as HSP90AA1, IGF1, MDM2, MET, and SPP1 were the ones involved in the PI3K-Akt signaling pathway. In GO-BP analysis, the DEARGs were mainly associated with the processes of response to hypoxia, response to nutrient levels, response to decreased oxygen levels, negative regulation of cellular component organization, response to extracellular stimulus, response to oxygen levels, autophagy, a process utilizing autophagic mechanism, etc. (Figure 4 and Table 2).

3.3 PPI network of analysis

In this study, we established a PPI network of DEARGs based on the STRING database and Cytoscape software to investigate the interactions of these targets and screen important targets of the network. As shown in Figure 5a, a PPI network contains 22 nodes and 45 edges. These DEARGs were ranked based on their degree values, and the top ten genes with the highest degrees, namely HSP90AA1, HIF1A, MET, IGF1, LRRK2, CLTC, DNMI1, MDM2, RICTOR, and ROCK2 (Figure 5b).

3.4 Validation of hub genes expression

The expression levels of hub genes in the GSE53408 dataset were validated to further confirm the reliability of the GSE113439 dataset. As shown in Figure 6, the expression levels of HSP90AA1, HIF1A, MET, IGF1, LRRK2, CLTC, DNMI1, MDM2, RICTOR, and ROCK2 were significantly lower in control samples than in PAH samples.

3.5 ROC curve analysis

To assess the sensitivity and specificity of the potential target for the diagnosis of PAH, the ROC analysis was performed. As a result, the AUC values of ten hub genes for PAH exceeded 0.8 in the GSE113439 dataset (Figure 7), which verifies the diagnostic value of hub genes (HSP90AA1, HIF1A, MET, IGF1, LRRK2, CLTC, DNMI1, MDM2, RICTOR).

Figure 4: Bubble diagram of GO-BP enrichment analysis of DEARGs.
Discussion

PAH is a serious cardiorespiratory disease evoked by multiple risk factors [20]. Epidemiological research has revealed that the 5-year overall survival rate of PAH sufferers is less than 60% [21]. Therefore, accurate classification and diagnosis are the necessary means to improve the overall survival rate. Although studies on PAH have increased and relevant studies have made some progress, the specific pathological mechanism of PAH is still unknown and the clinical treatment effect is not ideal [22].

Autophagy has been reported to be a key regulator in human pulmonary pathologies and is considered a potential therapeutic target [23]. The interplay between reactive oxygen species and autophagy plays a complex and important role in the pathogenesis of pulmonary diseases, including PAH [24].

Previous reports have indicated that pulmonary artery smooth muscle cell autophagy is associated with pulmonary vascular remodeling and implicated in the pathological process of PAH [25,26]. However, the role of autophagy in the pathological mechanism of PAH needs to be further investigated.

With the development of a high-throughput gene assay, genomics research has been carried out to investigate the pathogenesis of PAH. In this study, we employed bioinformatics approaches to analyze the gene expression profiles of the GSE113439 dataset and identified 26 DEARGs associated with the pathological mechanism of PAH. Besides, the top ten hub genes were further identified and verified by using the GSE53408 dataset.

We also performed the KEGG and GO-BP enrichment analyses to reveal the potential biological function of DEARGs in PAH. The findings of KEGG analysis indicated that the DEARGs were mainly enriched in the PI3K-AKT and NOD-like receptor signaling pathways, which were to the previous results that PI3K-AKT and NOD-like receptor were key signaling pathways in PAH [27,28]. Additionally, GO-BP analysis revealed that the DEARGs were markedly enriched in the autophagy and response to oxygen levels. Previous studies have demonstrated that autophagy is involved in the progression of PAH. For example, liraglutide has been shown to ameliorate PAH through the regulation of autophagy pathways [29]. NSD2 silencing could ameliorate PAH via inhibiting pulmonary artery autophagy [16]. Besides, autophagy activation helps with BMPR2 degradation and it plays a crucial role in the development of PAH [30].
In this study, ten hub genes (HSP90AA1, HIF1A, MET, IGF1, LRRK2, CLTC, DNM1L, MDM2, RICTOR, and ROCK2) associated with PAH were identified via PPI network analysis. We further confirmed the expression level of hub genes by using the GSE53408 dataset. These results were consistent with the bioinformatics analysis findings.

**Figure 5:** PPI network analysis of the DEARGs: (a) PPI network of DEARGs. The color and size of nodes indicate the value of a degree, the larger and deeper a node, the more important it is in the network. (b) Top ten genes of DEARGs by degree score ranking.

**Figure 6:** Verification expression levels of hub genes in GSE53408 dataset: (a) HSP90AA1, (b) HIF1A, (c) MET, (d) IGF1, (e) LRRK2, (f) CLTC, (g) DNM1L, (h) MDM2, (i) RICTOR, and (j) ROCK2. GSE53408 contains 11 healthy individuals and 12 severe pulmonary arterial hypertension patients. ***P < 0.001.

**Figure 7:** ROC analysis of ten hub genes: (a) the ROC curves of HSP90AA1, HIF1A, MET, IGF1, and LRRK2 in the diagnosis of PAH and (b) the ROC curves of CLTC, DNM1L, MDM2, RICTOR, and ROCK2 in the diagnosis of PAH.
from the GSE113439 dataset. In addition, these ten DEARGs showed a high diagnosis value in PAH. To date, few studies have reported that these genes are involved in the pathogenesis of pulmonary diseases via the regulation of autophagy. However, several studies have reported them to be related to pulmonary diseases or autophagy. For example, a recent study demonstrated that heat shock protein 90 α family class A member 1 (HSP90AA1) induces autophagy via inactivation of the AKT-MTOR pathway [31]. HSP90AA1 is a novel therapeutic target in PAH [32] A previous study reported degradation of hypoxia-inducible factor 1 subunit alpha (HIF1A) in the lysosome via chaperone-mediated autophagy [33]. HIF1A was reported to play a vital role in hypoxia-induced pulmonary hypertension [34]. A higher level of HIF1A in human pulmonary artery smooth muscle cells could increase susceptibility to developing PAH [35]. Mesenchymal-epithelial transition (MET) is important for autophagy regulation through the mTOR pathway [36]. MET has not been reported in PAH. However, the MET signaling pathway has been demonstrated as a potential pathway in non-small-cell lung cancer [37]. An inhibitory effect of insulin-like growth factor 1 (IGF1) on autophagy has been found in rat cardiomyocytes [38]. A previous report indicated that IGF1 prevents cell apoptosis in pulmonary artery smooth muscle cells during PAH [39]. IGF1 was also implicated in the pathogenesis of PAH in neonatal mice [40]. Leucine-rich repeat kinase 2 (LRRK2) has been involved in autophagy [41]. It has not been reported in PAH, but a previous report revealed that it might be a key gene that helps tumorigenesis in non-small-cell lung cancer [42,43].Alias for the DNM1L gene is dynamin-related protein 1 (DRP1). DRP1-dependent mitochondrial fission promotes pulmonary vascular remodeling via activating autophagy, indicating that DNM1L might be a therapeutic target for the treatment of PAH [44]. Murine double minute (MDM2) contributes to mitophagy of damaged mitochondria [45]. It has been reported that MDM2 and AMPK crosstalk is involved in the pathogenesis of PAH, and a combined intervention of MDM2 and AMPK might be a novel therapy in PAH treatment [46]. Rapamycin-insensitive companion of mTOR (RICTOR) amplification promotes non-small cell lung cancer proliferation via generation of mTORC2 [47]. Pharmacologic inhibition of Rho-associated protein kinase 2 (ROCK2) could induce autophagy [48]. ROCK2 regulates the cell cycle progression in hypoxia-induced PAH, suggesting it might be a novel target for improving PAH treatment [49]. To date, there is no relevant research that reported clathrin 1 gene (CLTC) is associated with lung diseases. Although potential DEARGs associated with PAH were identified based on bioinformatics, the experimental studies should be performed both in vitro and in vivo to further verify our findings.

5 Conclusion

Overall, our findings revealed HSP90AA1, HIF1A, MET, IGF1, LRRK2, CLTC, DNM1L, MDM2, RICTOR, and ROCK2 as potential diagnostic biomarkers and therapeutic targets for PAH. These findings broaden our understanding of the pathogenesis of PAH.

Funding information: Not applicable.

Conflict of interest: The authors declare no conflict of interest.

Data availability statement: All data are available from the corresponding author upon reasonable request.

References

[1] Zolty R. Pulmonary arterial hypertension specific therapy: the old and the new. Pharmacol Therapeutics. 2020;214:107576.
[2] Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017;14(10):603–14.
[3] Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respiratory J. 2019;53:1.
[4] Kanbayashi K, Minami Y, Haruki S, Maeda R, Itani R, Ashihara K, et al. Association of elevated pulmonary artery systolic pressure with stroke and systemic embolic events in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2017;240:320–3.
[5] Ong KC, Geske JB, Hebl VB, Nishimura RA, Schaff HV, Ackerman Mj, et al. Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. Eur heart J Cardiovascular Imaging. 2016;17(6):604–10.
[6] Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respiratory J. 2014;43(6):1691–7.
[7] Sitbon O, Sattler C, Bertoletti L, Savale L, Cottin V, Jaïs X, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respiratory J. 2016;47(6):1727–36.
[8] Wang T, Zheng X, Li R, Liu X, Wu J, Zhong X, et al. Integrated bioinformatic analysis reveals YWHAB as a novel diagnostic biomarker for idiopathic pulmonary arterial hypertension. J Cell Physiol. 2019;234(5):6449–62.
[9] Dong H, Li X, Cai M, Zhang C, Mao W, Wang Y, et al. Integrated bioinformatic analysis reveals the underlying molecular mechanism of and potential drugs for pulmonary arterial hypertension. Aging. 2021;13(10):14234–57.

[10] Kerkhof PLM, LI JK, Handly N. Interpretation of a new biomarker for the right ventricle introduced to evaluate the severity of pulmonary arterial hypertension. Pulmonary Circulation. 2019;9(2):2045894019826945.

[11] Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728–41.

[12] Racanelli AC, Klikkers SA, Choi AMK, Cloonan SM. Autophagy and inflammation in chronic respiratory disease. Autophagy. 2018;14(2):221–32.

[13] Liao SX, Sun PP, Gu YH, Rao XM, Zhang LY, Ou XM, et al. Activation of autophagy and mitophagy in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol. 2016;311(2):L433–52.

[14] Zhai C, Shi W, Feng W, Li MX, Jin LT, Wang TJ, Feng YJ, Pan CP, Zhao DM, et al. PDIA6 modulates ASK1 and inactivates AMPK, which prevents monocrotaline induced pulmonary arterial hypertension by inactivating the AKT/GSK3β signaling pathway. J Cell Physiol. 2018;233(12):8443–52.

[15] Xiao G, Zhuang W, Wang T, Lian G, Luo L, Ye C, et al. Transcriptomic analysis identifies Toll-like and Nod-like pathways and necroptosis in pulmonary arterial hypertension. J Cell Mol Med. 2020;24(19):11409–21.

[16] Zhou XL, Liu ZZ, Zhu RR, Huang H, Xu QR, Xu H, et al. NSD2 silencing alleviates pulmonary arterial hypertension by inhibiting trehalose metabolism and autophagy. Clinical Sci (London, England: 1979). 2019;133:1085–96.

[17] Zhai C, Shi W, Feng W, Zhu Y, Wang J, Li L, et al. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation. Life Sci. 2018;208:87–95.

[18] Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al.Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

[19] Li MX, Jin LT, Wang TJ, Feng YJ, Pan CP, Zhao DM, et al. Identification of potential core genes in triple negative breast cancer muscles using bioinformatics analyses. OncoTargets Ther. 2018;11:4015–12.

[20] de Jesus Perez VA. Molecular pathogenesis and current pathology of pulmonary hypertension. Heart Fail Rev. 2016;21(3):239–57.

[21] Galiè N, Humbert M, Vachieri JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary arterial hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPcC), International Society for Heart and Lung Transplantation (ISHLT), Eur Respiratory J. 2015;46(4):903–75.

[22] Xiao Y, Chen PP, Zhou RL, Zhang Y, Tian Z, Zhang SY. Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review. Aging Dis. 2020;11(6):1623–39.

[23] Aggarwal S, Mannam P, Zhang J. Differential regulation of autophagy and mitophagy in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol. 2016;311(2):L433–52.

[24] Ornatekowski W, Lu Q, Yegambaram M, Garcia AE, Zemskov EA, Maltepe E, et al. Complex interplay between autophagy and oxidative stress in the development of pulmonary fibrosis. Redox Biol. 2020;36:101679.

[25] Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655–65.

[26] Chen R, Jiang M, Li B, Zhong W, Wang Z, Yuan W, et al. The role of autophagy in pulmonary hypertension: a double-edge sword. Apoptosis Int J Program Cell Death. 2018;23(9–10):459–69.

[27] Wei L, Zhang B, Cao W, Xing H, Yu X, Zhu D. Inhibition of CXCL12/CXCR4 improves pulmonary arterial smooth muscle cell proliferation and cell cycle progression via PI3K/Akt pathway under hypoxia. J Receptor Signal Transduct Res. 2015;35(4):329–39.

[28] Xiao G, Zhuang W, Wang T, Lian G, Luo L, Ye C, et al. Transcriptomic analysis identifies Toll-like and Nod-like pathways and necroptosis in pulmonary arterial hypertension. J Cell Mol Med. 2020;24(19):11409–21.

[29] Wu YC, Wang WT, Lee SS, Kuo YR, Wang YC, Yen SJ, et al. Glucagon-like peptide-1 receptor agonist attenuates autophagy to ameliorate pulmonary arterial hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3β pathways. Int J Mol Sci. 2019;20:14.

[30] Gomez-Puerto MC, van Zuijlen I, Huang CJ, Szuzeck R, Pan X, van Dinther MA, et al. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension. J Pathol. 2019;249(3):356–67.

[31] Hu B, Zhang Y, Jia L, Wu H, Fan C, Sun Y, et al. Binding of the pattern receptor HSPO90AA1 to avibirnavirus VP2 induces autophagy by inactivating the AKT-MTOR pathway. Autophagy. 2015;11(3):503–15.

[32] Yao X, Jing T, Wang T, Gu C, Chen X, Chen F, et al. Molecular characterization and elucidation of pathways to identify novel therapeutic targets in pulmonary arterial hypertension. Front Physiol. 2021;12:694702.

[33] Ferreira JV, Fôło H, Bejarano E, Bento CF, Ramalho JS, Girão H, et al. STUB1/CHIP is required for HIF1A degradation by chaperone-mediated autophagy. Autophagy. 2013;9(9):1349–66.

[34] Smith KA, Yuan JX. Hypoxia-inducible factor-1a in pulmonary arterial smooth muscle cells and hypoxia-inducible pulmonary hypertension. Am J Respir Crit Care Med. 2014;189(3):245–6.

[35] Docherty CK, Nilsen M, MacLean MR. Influence of 2-methoxyestradiol and sex on hypoxia-induced pulmonary hypertension and hypoxia-inducible factor-1α. J Am Heart Assoc. 2019;8(5):e011628.

[36] Gallo S, Sala V, Gatti S, Crepaldi T. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. Clinical Sci (London, England: 1979). 2015;129:1173–93.

[37] Gelsomino F, Facchinetti F, Haspinger ER, Garassini MC, Trusolino L, De Braud F, et al. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol/Hematol. 2014;89(2):284–99.

[38] Troncoso R, Vicenço JM, Parra V, Nemchenko A, Kawashima Y, Del Campo A, et al. Energy-preserving effects of IGF-1 antag- onize starvation-induced cardiac autophagy. Cardiovascular Res. 2012;93(2):320–9.

[39] Jin C, Guo J, Qiu X, Ma K, Xiang M, Zhu X, et al. IGF-1 induces iNOS expression via the p38 MAPK signal pathway in the anti-apoptotic process in pulmonary artery smooth muscle cells.
during PAH. J receptor Signal Transduct Res. 2014;34(4):325–31.

[40] Yang Q, Sun M, Ramachandran R, Raj JU. IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: role of epigenetic regulation. Vasc Pharmacol. 2015;73:20–31.

[41] Manzoni C, Lewis PA. LRRK2 and autophagy. Adv Neurobiol. 2017;14:89–105.

[42] Ma Q, Xu Y, Liao H, Cai Y, Xu L, Xiao D, et al. Identification and validation of key genes associated with non-small-cell lung cancer. J Cell Physiol. 2019;234(12):22742–52.

[43] Jung K, Choi JS, Koo BM, Kim YJ, Song JY, Sung M, et al. TM4SF4 and LRRK2 are potential therapeutic targets in lung and breast cancers through outlier analysis. Cancer Res Treat. 2021;53(1):9–24.

[44] Feng W, Wang J, Yan X, Zhang Q, Chai L, Wang Q, et al. ERK/Drp1-dependent mitochondrial fission contributes to HMGB1-induced autophagy in pulmonary arterial hypertension. Cell Prolif. 2021;54(6):e13048.

[45] Kook S, Zhan X, Thibeault K, Ahmed MR, Gurevich VV, Gurevich EV. Mdm2 enhances ligase activity of parkin and facilitates mitophagy. Sci Rep. 2020;10(1):5028.

[46] Shen H, Zhang J, Wang C, Jain PP, Xiong M, Shi X, et al. MDM2-mediated ubiquitination of angiotensin-converting enzyme 2 contributes to the development of pulmonary arterial hypertension. Circulation. 2020;142(12):1190–204.

[47] Kim LC, Rhee CH, Chen J. RICTOR amplification promotes NSCLC cell proliferation through formation and activation of mTORC2 at the expense of mTORC1. Mol Cancer Res MCR. 2020;18(11):1675–84.

[48] Weber AJ, Herskowitz JH. Perspectives on ROCK2 as a therapeutic target for Alzheimer’s disease. Front Cell Neurosci. 2021;15:636017.

[49] Qiao F, Zou Z, Liu C, Zhu X, Wang X, Yang C, et al. ROCK2 mediates the proliferation of pulmonary arterial endothelial cells induced by hypoxia in the development of pulmonary arterial hypertension. Exp Therapeutic Med. 2016;11(6):2567–72.